Altana Pharma AG v. Teva Pharmaceuticals USA, Inc.
United States Court of Appeals for the Federal Circuit
566 F.3d 999 (2009)
- Written by Rich Walter, JD
Facts
A patented process winnowed a field of 90 chemical compounds to 18 compounds that seemed especially effective in neutralizing gastric acid. Of these 18 compounds, Altana Pharma AG (Altana) (plaintiff) isolated “compound 12” and turned it into the patented active ingredient of a prescription drug. When Teva Pharmaceuticals USA, Inc. (Teva) (defendant) announced plans to market a competing generic version of Altana’s patented drug, Altana sued Teva for patent infringement. Altana argued that the prior art did not point to compound 12 as the single best candidate for improvement. Teva introduced expert testimony that multiple sources would have led a person having ordinary skill in the art to reason that compound 12 was at least one of several promising candidates for further research. The federal district court found enough merit in Teva’s obviousness defense to deny Altana’s motion for a preliminary injunction. Altana appealed to the Federal Circuit.
Rule of Law
Issue
Holding and Reasoning (Ward, J.)
What to do next…
Here's why 812,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,300 briefs, keyed to 988 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.